Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many\nadvance-stage epithelial cancers. These agents have the superior ability to target cancers cells and better safety profile compared\nto conventional chemotherapies. However, cutaneous adverse events are common due to the interference of epidermal growth\nfactor receptor (EGFR) signaling in the skin. Cutaneous toxicities lead to poor compliance, drug cessation, and psychosocial\ndiscomfort. This paper summarizes the current knowledge concerning the presentation and management of skin toxicity from\nEGFRI.Thecommon dermatologic adverse events are papulopustules and xerosis. Less common findings are paronychia, regulatory\nabnormalities of hair growth, maculopapular rash, mucositis, and postinflammatory hyperpigmentation. Radiation enhances\nEGFRI rash due to synergistic toxicity. There is a positive correlation between the occurrence and severity of cutaneous adverse\neffects and tumor response. To date, prophylactic systemic tetracycline and tetracycline class antibiotics have proven to be the most\neffective treatment regime.
Loading....